<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891302</url>
  </required_header>
  <id_info>
    <org_study_id>BK-CLV-203</org_study_id>
    <nct_id>NCT04891302</nct_id>
  </id_info>
  <brief_title>The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19</brief_title>
  <official_title>A Double Blind, Randomized, Placebo-controlled, Multi-center, Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Mild and Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 150 mg&#xD;
      versus placebo once daily administration with standard of care therapy for 10 days in&#xD;
      patients with mild and moderate COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The amount of SARS-CoV-2 virus reduction on Day 11 compared to the the baseline.</measure>
    <time_frame>Day 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time consumed for clinical improvement.</measure>
    <time_frame>Day 4, Day 8, Day 11, Day 15, Day 22 and Day 29 (or EOT)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects tested as negative SARS-CoV-2 in consecutive two days of Real-Time RT-PCR tests.</measure>
    <time_frame>Day 4, Day 8, Day 11, Day 15, Day 22 and Day 29 (or EOT)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of SARS-CoV-2 virus reduction on Day 4, Day 8, Day 15, Day 22 and Day 29 compared to the the baseline.</measure>
    <time_frame>Day 4, Day 8, Day 15, Day 22 and Day29 (or EOT)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects indicated by the improvement of lung invasive.</measure>
    <time_frame>Within Day 29 (or EOT)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cycle threshold values change from baseline.</measure>
    <time_frame>Day 4, Day 8, Day 11, Day 15, Day 22 and Day29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The viral load change from baseline.</measure>
    <time_frame>Day 4, Day 8, Day 11, Day 15, Day 22 and Day29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The C-reactive protein change from baseline.</measure>
    <time_frame>Day 4, Day 8, Day 11, Day 15, Day 22 and Day29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The procalcitonine change from baseline.</measure>
    <time_frame>Day 4, Day 8, Day 11, Day 15, Day 22 and Day29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who received new oxygen supplement at visit after baseline.</measure>
    <time_frame>Day 4, Day 8, Day 11, Day 15, Day 22 and Day 29 (or EOT)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time of subjects discharged from the hospital.</measure>
    <time_frame>Day 4, Day 8, Day 11, Day 15, Day 22 and Day 29 (or EOT)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Clevudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clevudine 150 mg once a day for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo once a day for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevudine</intervention_name>
    <description>Clevudine 150mg (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days</description>
    <arm_group_label>Clevudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Over 19 years of age&#xD;
&#xD;
          2. COVID-19 confirmed by a real-time RT-PCR tests, and hospitalized&#xD;
&#xD;
          3. Patients who experienced first symptom related to COVID-19 within 7days prior to&#xD;
             enrollment and confirmed 2 or more relative symptoms at the time of randomization.&#xD;
&#xD;
          4. Patients with peripheral capillary oxygen saturation(SpO2) greater than 94% at the&#xD;
             time of screening, who do not need supplemental oxygen therapy.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Patients who participated in other clinical trials related to COVID-19&#xD;
&#xD;
          2. Patients who were administered drugs directly to COVID-19 24hours prior to the start&#xD;
             of the study.&#xD;
&#xD;
          3. Patients who need oxygen supply or breathing device (non-invasive mechanical&#xD;
             ventilation(via mask)), mechanical ventilator requirement (via endotracheal tube or&#xD;
             tracheostomy tube, ECMO requirement) at the time of screening or baseline&#xD;
&#xD;
          4. Patients whose AST or ALT has increased by more than 5 times the normal lab value.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bukwang Pharma. Bukwang Pharma.</last_name>
    <phone>+82-2-828-8114</phone>
    <email>bk.E106@bukwang.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeon sook Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung Yeon Heo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won-suk Choi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Myongji Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki-deok Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joong-Sik Eom</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Incheon Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Young Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Soo Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-kyung Yoon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woo-Joo Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donghui Choi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clevudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

